SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

~~February~~June 16, 2016

EVENT CARDIO GROUP INC.
(Exact name of registrant as specified in its charter)

Nevada	0-52518	20-8051714
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

739 Colony Palm Drive

Boynton Beach, Florida

33436

(Former address of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~FORWARD~~Item ~~LOOKING~~1.01 ~~STATEMENTS~~Entry into a Material Definitive Agreement.

~~Information included in this~~Share ~~Form~~Purchase ~~8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act~~ and ~~Section~~Option 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Event Cardio Group Inc. and its subsidiaries (collectively, “ECGI”, “We”, “Our” or the “Company”) to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe ECGI’s future plans, strategies and expectations, are generally identifiable by use of words "may," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. ECGI’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, ECGI undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.Agreement

~~Item~~On June 216, 2016, Event Cardio Group Inc.01, ~~Entry~~a Nevada corporation (the “Company”), and certain of its affiliated entities, entered into, and consummated the transactions contemplated by, a ~~Material~~Share Purchase ~~Definitive~~and Option Agreement (the “Agreement”) with Nick Bozza, individually and as nominee of the Nick Bozza Family Trust (collectively, “Mr. Bozza”), filed as exhibit 10.1 to this report. Pursuant to the Agreement, Mr. Bozza relinquished his rights under a license granted by the Company in 2014 to market and distribute the Company’s wireless cardiac monitoring device in Canada, exclusively within the Province of Ontario, and to the repayment of certain indebtedness of the Company and its affiliated entities. Each of the parties also released all claims which it may have against each of the other parties to the Agreement. In addition, Mr. Bozza sold to the Company 20,000,000 shares of the Company’s common stock, together with shares of the affiliated entities. In addition, Mr. Bozza granted the Company an option to purchase the remaining 9,812,500 shares of the Company’s common stock owned by him for a purchase price of US$500,000 at any time prior to May 6, 2018. For all the rights acquired, in addition to releasing Mr. Bozza from any claims it may have against him, the Company paid Mr. Bozza CAD $1,025,000, or approximately US $850,000.

~~Event Cardio Group Inc. has entered into~~ Subscription Agreements with ten individuals who have agreed to pay an aggregate of Cdn$1,500,000 (US$1,082,251) for an aggregate of 16,901,400 million shares of the Company’s common stock and 10,000,000 warrants to purchase shares of the Company’s common stock. The Warrants are exercisable until February 28, 2019, at an exercise price of US$0.15 per share. The Subscription Agreements provide for monthly payments to be made to the Company in accordance with a schedule attached to the Subscription Agreements and, to date, the investors have remitted an aggregate of Cdn$335,000 (US$241,702) to the Company. The form of Subscription Agreements and Warrants have been filed as Exhibits to this report.

~~The~~On June ~~Company~~16, ~~anticipates that the majority~~2016, of the ~~proceeds~~Company ~~received~~sold to ~~from~~Zhenli ~~the~~Xu, a ~~investors~~citizen ~~will~~of China, be2,500,000 ~~used~~shares of ~~to finalize~~ the ~~development~~Company’s common ofstock ~~its heart monitor~~ and warrants ~~activities~~to ~~necessary~~purchase toan ~~finalize~~additional ~~and~~833,333 shares ~~submit~~of ~~the~~common stock, ~~application~~ for ~~approval~~a purchase toprice ~~HealthCare~~of $375,000, ~~Canada~~pursuant ~~and~~to a ~~510(k)~~subscription ~~application~~agreement tofiled ~~the~~as ~~United~~exhibit ~~States FDA~~10.2 ~~The Company anticipates that it will require additional investments~~ to ~~commence~~this ~~commercial~~report. The ~~distribution~~warrants ofmay be ~~its~~exercised ~~heart~~at ~~monitor~~any ~~and~~time ~~the software~~prior to beDecember ~~used~~31, to2019 ~~process~~at ~~information~~an ~~received~~initial ~~from~~exercise ~~patients~~price ~~wearing~~of ~~the~~$0.25 ~~heart~~per ~~monitor~~share.

~~As a condition to~~On ~~the~~June ~~subscription by the investors~~15, ~~2399371 Ontario Inc.~~2016, ~~which inclusive of accrued interest is due Cdn$960,300 (US$692,857)~~ ~~from~~ the Company, ~~agreed~~ sold to ~~extend~~entities ~~the~~controlled by ~~due~~each ~~date~~ of Ian ~~all~~Genoa ~~amounts owed until January 31, 2018. 23999371 Ontario Inc.~~ and ~~the~~ ~~Company~~Michael ~~entered~~Ho ~~into a 12% Convertible Promissory Note in substitution for the Notes currently evidencing the amounts due the~~an ~~lender.~~aggregate ~~Further, in the Convertible Promissory Note 2399371 Ontario Inc. waived its right to receive any~~ of ~~the proceeds from~~10,000,000 ~~the~~shares ~~amounts to be received from the current investors and from any future issuances~~ of ~~equity or debt made by~~ the Company~~. In~~’s ~~consideration~~common ofstock ~~the~~and warrants ~~concessions made by 2399371 Ontario Inc., the Company agreed that it would have the right~~ to ~~convert the~~purchase ~~principal~~an ~~amounts~~aggregate ~~due~~of 5,000,000 ~~and all interest accrued thereon into~~ shares of common stock, offor a ~~the~~total ~~Company at an initial conversion~~purchase price of ~~Cdn~~$~~0.0873 per share and issued to it a warrant to purchase 3~~1,000,000, ~~shares~~pursuant ofto ~~the~~subscription ~~Company’s~~agreements ~~common~~filed ~~stock exercisable~~as ~~until~~exhibits ~~February~~10.4 and 2810.6, ~~2019~~respectively, atto athis ~~price~~report. ofThe ~~US$0.01~~warrants ~~per~~may ~~share.~~be Aexercised ~~copy~~at ofany ~~the~~time ~~12%~~prior ~~Convertible~~to ~~Promissory~~May ~~Note~~26, ~~and warrant~~2019 ~~have~~at ~~been~~an ~~filed~~initial asexercise price ~~exhibits~~of to$0.25 ~~this~~per ~~report~~share.

AsItem an3.02 ~~additional~~Unregistered ~~condition~~Sales ~~to the investment by the ten investors, John Bentivoglio, currently the sole director~~ of ~~the~~Equity Company, agreed to amend his Employment Agreement and to appoint additional directors to the Company’s Board in consultation with Frank Sgro and Gino Alberelli, the representatives of the lender and ten investors, respectivelySecurities. ~~It is anticipated that the additional directors will only begin to serve at such time as the Company has obtained directors’ and officers’ insurance in amounts acceptable to the new directors.~~

~~Mr. Bentivoglio’s Employment Agreement~~On ~~will~~June ~~be revised to provide for a term of 2 years commencing February 1~~16, 2016~~. His salary for~~ , the ~~first~~Company ~~year will be US$100~~sold 2,500,000 ~~and~~ ~~for~~shares of the ~~second~~Company’s common ~~year~~stock ~~will~~and warrants beto ~~determined~~purchase an noadditional ~~later~~833,333 shares ~~than the end~~ of ~~January~~common stock ~~2017~~to inZhenli Xu, ~~consultation~~a ~~with the Board~~ citizen of ~~Directors of the Company. In addition~~China, ~~Mr. Bentivoglio will be entitled to receive~~ for a ~~bonus~~purchase price of $~~225~~375,000 ~~when the Company achieves profitable operations~~. The warrants ~~bonus~~may ~~will~~ be exercised ~~paid~~at byany ~~remitting~~time prior to ~~Mr.~~December 31, ~~Bentivoglio~~2019 ~~25%~~at an ofinitial ~~the~~exercise price ~~Company’s profits in excess~~ of $~~200,000 until~~0.25 ~~the~~per ~~bonus has been satisfied~~share. IfThe shares ~~the~~and ~~Company~~warrants were is sold ~~before~~pursuant to the ~~bonus~~exemption ~~has~~from registration ~~been~~provided ~~paid~~by Regulation inS ~~full,~~promulgated under Mrthe Securities Act. ~~Bentivoglio~~The ~~will~~Company did benot ~~paid such~~pay ~~amount~~any ~~out~~sales ofcommissions ~~the proceeds of the sale~~ or, broker fees in connection with the issuance ~~event~~ of ~~a stock sale, out of~~ the shares ~~Company’s~~and ~~cash on hand~~warrants. The Ifcertificates ~~Mr. Bentivoglio~~evidencing ~~leaves~~ the ~~employ~~shares of and the ~~Company~~warrants ~~before~~were ~~the~~endorsed with ~~bonus~~a islegend restricting ~~paid~~their insale or ~~full,~~other ~~it will be paid at such time as the conditions to payment are~~disposition ~~met,~~without ~~provided~~compliance ~~he is then not competing~~ with the ~~Company.~~registration ~~The~~requirements ~~revisions~~of ~~to Mr. Bentivoglio’s Employment Agreement are currently~~the ~~being~~Securities ~~documented~~Act ~~and~~or ~~the amendment will be filed as~~ an ~~Exhibit~~exemption ~~to an amendment to this Report~~therefrom.

AsOn ~~an inducement to Mr. Bentivoglio~~June to15, ~~amend~~2016, ~~his employment agreement~~ the Company ~~issued~~sold toan aggregate ~~him~~of ~~a Warrant to purchase 3~~10,000,000 shares of the Company’s common stock ~~exercisable~~and ~~until~~warrants to ~~February~~purchase ~~28,~~an additional ~~2019~~5,000,000 ~~at a price~~ shares of ~~$.01~~common ~~per share. In addition, for consultation services previously rendered~~stock to ~~the~~entities ~~Company~~controlled by Ian Genoa and ~~his~~Michael ~~agreement~~Ho. The towarrants ~~continue~~may be toexercised ~~consult~~at ~~with~~any time ~~the~~prior ~~Company, the Company has agreed~~ to ~~issue Warrants to purchase~~ ~~2,000,000~~May ~~shares of the Company’s common stock exercisable until February 28~~26, 2019 at aan initial exercise price of $0.0125 per share ~~to Mr~~. ~~Gino~~The ~~Alberelli.~~shares Asand warrants anwere ~~inducement~~sold pursuant to ~~future~~the ~~efforts~~exemption from onregistration ~~behalf~~provided by ofRegulation ~~the~~S promulgated ~~Company,~~under the Securities Act. The Company ~~has~~did ~~agreed~~not pay toany ~~issue~~sales ~~Warrants~~commissions or tobroker ~~purchase~~fees ~~2,000,000~~in ~~shares~~connection of with the ~~Company’s~~issuance ~~common stock exercisable until February 28, 2019 at a price~~ of the $0shares and warrants.01 ~~per~~The ~~share to each~~certificates ofevidencing ~~Richard~~the ~~Smith~~ shares and ~~Ricardo~~the ~~Rodriguez,~~warrants ~~engineers~~were endorsed atwith ~~Contex~~a legend ~~Engineering,~~restricting ~~which~~their sale ~~has~~or ~~been~~other disposition ~~developing~~without ~~the Company’s hear monitor,~~compliance ~~and~~with the ~~Company’s~~registration requirements ~~counsel,~~of ~~except that~~ the ~~Warrants~~Securities ~~issued~~Act toor ~~counsel~~an ~~are~~exemption ~~exercisable at US$0~~therefrom.~~03 per share.~~

Item 87.01 ~~Other~~Regulation ~~Events~~FD Disclosure.

~~Dispute~~On June 21, 2016, the Company issued a press release with ~~Life~~respect ~~Medical~~to the transactions described in Items 1.01 and 3.02 of this report. The press release is attached as Exhibit 99.1 to this report.

The ~~Company~~information ~~anticipates~~in ~~that~~Exhibit it99.1 ~~will devote the majority of the~~shall ~~proceeds~~not ~~received~~be ~~from~~deemed ~~the~~as ~~current~~“filed” ~~ten~~for ~~investors~~purposes toof ~~the~~Section 18 ~~development~~ of ~~its heart monitor and obtaining~~ the ~~regulatory~~Securities ~~approvals necessary~~Exchange toAct ~~market~~of ~~the~~1934 ~~product in Canada and~~ (the ~~United States. Further~~“Exchange Act”), ~~until~~or ~~the~~otherwise ~~Company~~subject ~~has received the necessary approvals and sufficient amounts~~ to ~~commence~~ the ~~marketing~~liability of ~~its~~such ~~heart monitor~~Section, itnor isshall ~~not~~it ~~likely~~be todeemed ~~devote~~incorporated ~~significant~~by ~~time~~reference orin ~~monies~~any tofiling ~~Life~~by ~~Medical’s~~us ~~Technologies’~~under ~~BreastCare®.~~the ~~Life~~Securities ~~Medical~~Act ~~contends~~of ~~that~~1933, ~~the~~as ~~Company~~amended, ~~acting~~or ~~through its subsidiary which is party to~~ the ~~License~~Exchange ~~Agreement with Life Medical~~Act, isregardless ~~in default~~ of ~~its~~any ~~obligations~~general ~~under~~incorporation ~~the~~language ~~License~~in ~~Agreement and owes~~such ~~Life Medical an aggregate of approximately $800~~filing,~~000~~ inunless ~~respect~~expressly ofincorporated ~~minimum~~by ~~royalties~~specific ~~due~~reference in ~~January~~such ~~2016, and amounts payable as a result of the failure to timely develop the territories which are the subject of the License Agreement between the Company and Medpac Asia Pacific Pty, Ltd~~filing.

The Company’s subsidiary is currently in litigation with Life Medical over the status of the License Agreement between them. As the litigation is in the preliminary stage, there is no assurance that there will be a successful outcome. Unless the Company were to achieve a favorable result in this litigation or achieve a settlement with Life Medical, which is doubtful if the Company does not raise significant monies for development of Breastcare® in the immediate future, it is likely that the Company will lose or forfeit its right to distribute BreastCare®.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
10.1		~~Form~~Share ofPurchase ~~Subscription~~and Option Agreement dated June 16, 2016
10.2		~~Form~~Subscription ofAgreement ~~Warrant~~with ~~issued~~Zhenli ~~to Investors~~Xu.
10.3		~~12%~~Warrant ~~Convertible~~issued ~~Promissory~~to ~~Note~~Zhenli Xu.
10.4		~~Warrant~~Subscription ~~issued~~Agreement towith ~~2399371~~2008817 Ontario ~~Inc~~Limited.
10.5		~~Form~~Warrant ~~of warrant~~ issued to ~~Messrs.~~2508817 ~~Alberelli,~~Ontario ~~Bentivoglio, Rodriguez, Smith and Counsel~~Limited.
10.6		Subscription Agreement with 1789134 Ontario Limited.
10.7		Warrant issued to 1789134 Ontario Limited.
99.1		Press release issued on June 21, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~February~~June 1622, 2016

	EVENT CARDIO GROUP INC.

	By:	/s/ John Bentivoglio
		John Bentivoglio
		Chief Executive Officer

Filing Compare · Event Cardio Group Inc.